$3.36
1.82% yesterday
Nasdaq, Sep 27, 10:16 pm CET
ISIN
NL0010872420
Symbol
AFMD
Sector
Industry

Affimed N.V. Stock price

$3.36
-0.84 20.00% 1M
-1.97 36.96% 6M
-2.89 46.24% YTD
-1.39 29.26% 1Y
-58.84 94.60% 3Y
-28.59 89.48% 5Y
-58.54 94.57% 10Y
Nasdaq, Closing price Fri, Sep 27 2024
+0.06 1.82%
ISIN
NL0010872420
Symbol
AFMD
Sector
Industry

Key metrics

Market capitalization $50.25m
Enterprise Value $28.89m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 9.93
P/S ratio (TTM) P/S ratio 17.27
P/B ratio (TTM) P/B ratio 1.68
Revenue growth (TTM) Revenue growth -91.10%
Revenue (TTM) Revenue $2.91m
EBIT (operating result TTM) EBIT $-91.56m
Free Cash Flow (TTM) Free Cash Flow $-93.56m
Cash position $36.92m
EPS (TTM) EPS $-4.09
P/E forward negative
P/S forward 13.73
EV/Sales forward 7.89
Short interest 4.86%
Show more

Is Affimed N.V. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

Affimed N.V. Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a Affimed N.V. forecast:

4x Buy
80%
1x Hold
20%

Analyst Opinions

5 Analysts have issued a Affimed N.V. forecast:

Buy
80%
Hold
20%

Financial data from Affimed N.V.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
2.91 2.91
91% 91%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 14 14
46% 46%
470%
- Research and Development Expense 73 73
39% 39%
2,501%
-88 -88
24% 24%
-3,009%
- Depreciation and Amortization 4 4
40% 40%
137%
EBIT (Operating Income) EBIT -92 -92
22% 22%
-3,146%
Net Profit -86 -86
27% 27%
-2,944%

In millions USD.

Don't miss a Thing! We will send you all news about Affimed N.V. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Affimed N.V. Stock News

Neutral
GlobeNewsWire
18 days ago
MANNHEIM, Germany, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that its Chief Executive Officer, Shawn M. Leland, PharmD, RPh, will participate in a fireside chat at the Cantor Global Healthcare Conference 2024 on Tues...
Neutral
Seeking Alpha
22 days ago
Affimed N.V. (NASDAQ:AFMD ) Q2 2024 Earnings Conference Call September 5, 2024 8:30 AM ET Company Participants Alex Fudukidis - Head, Investor Relations Shawn Leland - Chief Executive Officer Andreas Harstrick - Chief Medical Officer Michael Wolf - Vice President, Finance Conference Call Participants Maury Raycroft - Jefferies Daina Graybosch - Leerink Partners Bill Jahangiri - Truist Securitie...
Neutral
GlobeNewsWire
23 days ago
MANNHEIM, Germany, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today reported financial results and provided an update on clinical and corporate progress for the quarter ended June 30, 2024.
More Affimed N.V. News

Company Profile

Affimed NV engages in discovering and developing of targeted cancer immunotherapies. Its pipelines include Innate Cell Engagers and T Cell Engagers. The company was founded in 2000 and is headquartered in Heidelberg, Germany.

Head office Netherlands
CEO Shawn Leland
Employees 78
Founded 2000
Website www.affimed.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today